The discovery of the Philadelphia chromosome and its consistent involvement in chronic myeloid leukemia (CML) was the first time that a relationship between a cytogenetic abnormality and malignancy was demonstrated. This review will try to provide an insight into the molecular mechanisms underlying this disease and outline the therapeutical options for patients with CML.
Introduction: chronic myeloid leukemia
During the last decades it has become clear that most if not all cancers have a genetic origin. 1 One of the most paradigmatic examples is chronic myeloid leukemia (CML). The discovery of the Philadelphia chromosome 2 and its consistent involvement in CML 3 was the first time that a relationship between a cytogenetic abnormality and malignancy was demonstrated. This review will try to provide an insight into the molecular mechanisms underlying this disease and outline the therapeutical options for patients with CML.
General background

Clinical aspects
Chronic myeloid leukemia is a myeloproliferative disease which originates in a hematopoietic stem cell. 4 Patients with CML are often diagnosed after a routine blood control when a raised leukocyte count is found. 5 Staining of the blood smear shows a predominance of mature myeloid cells and sometimes the platelet count is elevated. Often the patients do not have any complaints at the time of diagnosis. However, suppression of normal hematopoiesis can lead to symptoms related to bone marrow failure such as fatigue and bleeding. Spleen enlargement caused by extra-medullary hematopoiesis can cause symptoms related to mechanical problems and high leukocyte numbers may lead to leukostasis.
The leukocytosis can easily be controlled by mild oral chemotherapeutic treatment with agents such as hydroxy-urea and busulfan. However, this apparent benign behavior changes dramatically 1-4 years after diagnosis when the disease progresses via an accelerated phase 6 towards the socalled blastic phase. The blastic phase is very reminiscent of an acute leukemia but is therapy resistant and is characterized by a median survival of about 18 weeks. 7 The life expectancy of CML patients is about 4 years although great variability exists depending on the time to acquire the blast crisis; about 10% of all CML patients live longer than 8 years. 8 The peak
Correspondence: GJ Ossenkoppele; Fax: 31-20-4442601 Received 9 March 1999; accepted 20 July 1999 incidence of CML is between 40 and 60 years, males are 1.4 times more likely to acquire this disease and it comprises about 20% of all leukemias. There are no answers as to why people develop CML although an increased incidence has been observed among survivors of atomic disasters.
The Philadelphia chromosome
The Philadelphia chromosome (Ph) is the result of a reciprocal recombination between chromosome 9 and 22, generating a shortened chromosome 22, the Ph chromosome and an elongated chromosome 9, 9q+. It can be detected in more than 90% of CML patients, 20-30% of adult lymphoblastic leukemia (ALL) patients and in 2-10% of childhood ALL. 9 Rare cases of Ph-positive acute myeloid leukemia have also been described [10] [11] [12] although these cases could also represent a myeloid blast crisis of a Ph-positive CML. 13, 14 Even more exceptional are Ph-positive cases of multiple myeloma, 15 nonHodgkin lymphomas 16 and myelodysplastic syndromes. 17, 18 It has been demonstrated that the breakpoints on chromosome 9 are located in the first and second intron of the c-abl gene. As a result of the translocation a part of the c-abl gene is translocated to chromosome 22 giving rise to the formation of the Ph chromosome. 19 The breakpoints on chromosome 22 are clustered in three regions, the minor breakpoint cluster region (mbcr), the major breakpoint cluster region (Mbcr) and the breakpoint cluster region (bcr). 20 All these are located in the bcr gene 21 (see Figure 1 ). Thus the reciprocal translocation gives rise to the formation of two new chimeric genes, ie the bcr-abl gene on the Ph and the abl-bcr gene on the 9q+.
The c-abl gene:
The c-abl gene is located on chromosome 9. The name is derived from the Abelson virus, containing the viral oncogene v-abl, which causes leukemia in mice. 22 The human homologue of the oncogenic sequence of v-abl is called the c-abl gene. It comprises two alternative first exons, 1a and 1b, and the common exons 2 to 11. An exceptionally long first intron spaces the first exon (1b) 200 kb 5Ј from exon 1a 9 (see Figure 1 ). Due to alternative splicing two transcripts can be formed called 1a and 1b of 6 kb and 7 kb, respectively. 23 The c-abl gene is ubiquitously expressed with the highest mRNA levels in spleen, thymus and testis. The two mRNA molecules encode two proteins of about 145 kDa in size. These proteins belong to the family of non-receptor tyrosine kinases. The b form is myrostilated at an amino terminal glycine residue which directs the protein to the plasma membrane. The ABL protein, containing the aminoterminal part encoded by exon 1a, lacks the myrostilation signal and is predominantly present in the nucleus. 24 Several distinct motifs present in both proteins can be identified (see Figure 2) . At the amino terminal part of the protein a src homology 3 (SH3) domain is present. SH3 domains are known to be involved in protein-protein interactions and can bind specifically to proline residue-rich stretches. 25 Adjacent a SH2 domain can be identified. SH2 domains can bind to phosphorylated tyrosine residues thereby linking proteins, enabling these to interact with each other. 26 Carboxyterminal of the SH2 a SH1/tyrosine kinase domain is present. Between residue 525 and 717 three proline-rich stretches can be identified, known as abl binding sites 1, 2 and 3, which can bind to other SH3 containing proteins. Between ab2 and ab3 a nuclear localization signal (NLS) is present which can direct the protein to the nucleus. Closer to the carboxyterminal end a stretch of acidic residues can be identified, involved in the binding of the abl protein to DNA. Lastly, at the carboxyterminal end an actin binding site is present. 27 The ABL protein has a function in cell cycle regulation. 28 In G 0 the ABL protein is DNA bound in complex with the retinoblastoma (Rb) protein, one of the ABL inhibiting proteins. During transition from G 1 to S the Rb is phosphorylated and dissociates from ABL 29 giving rise to the activation of the tyrosine kinase activity of the ABL protein. The activated ABL Review SFT Thijsen et al 1648 protein can subsequently alter transcription, for example, by phosphorylating RNA polymerase. 30 ABL is phosphorylated itself by CDC2 kinases 31 after which the ABL protein dissociates from the DNA and the cell progresses to the S phase. 32 Overexpression of the c-abl gene does not result in malignant transformation but in cell cycle arrest, 33, 34 very reminiscent of the behavior of tumour suppressor genes such as P53 and Rb. These results suggest a role for ABL as a negative regulator of cell growth. Interestingly, the growth suppressive potential of bcr-abl seems to depend on p53 and Rb activity. 35, 36 However, in contrast to the Rb and P53, disruption of the abl gene in mice does not lead to marked tumor proneness but to perinatal mortality and lymphopenia. 37, 38 Moreover, treatment of CD34-positive cells with antisense oligonucleotides directed against c-abl induce a specific inhibition of cell cycle entry into S phase. 39 The fact that mice can live without c-abl suggests that some of the c-abl functions are redundant and a rescue by arg (abl-related gene) has been suggested. 40 The bcr gene:
The bcr (breakpoint cluster region) was first identified as a region on chromosome 22 involved in the bcrabl translocation. 21 Subsequently, it was demonstrated that the bcr region is part of a gene later called the bcr gene. It spans a region of 135 kb and comprises 23 exons 9 ( Figure 1 ). The bcr gene belongs to a family of genes with unclear function encompassing the bcr 2, bcr 3 and bcr 4 genes. 41 Gene expression gives rise to two mRNA types of 4.5 and 6.7 kb which are both translated into a 160 kDa protein. 42 Li et al 43 showed that in human cells several different BCR proteins can be identified ranging in size from 83 to 190 kDa. The bcr gene is ubiquitously expressed in all human tissues. Several distinct structural regions can be identified in the BCR protein (see Figure 2) . At the amino terminal site a dimerisation domain (dd) is present which is involved in coiled-coil oligomerization of the BCR protein, 44 followed by a domain which can bind at the SH2 domain of c-abl in a non-phosphotyrosine-dependent manner, 45 followed by a region with a unique serine/threonine kinase activity, 46 a region of homology with Rho guanine-nucleotide exchange factors (Rho-GEF), 47 a region which might be involved with calcium-dependent lipid binding (CaLB), and a region which is implicated with Rac-GTPase activating protein (Rac-GAP) function. 48 BCR protein is localized in the cytoplasm in noncycling cells, while in mitosis the BCR protein can be detected perichromosomal, suggesting a role in cell cycle regulation. 49 The bcr-abl gene:
In the majority of CML patients breakpoints in intron 1 or 2 of the abl gene and in the Mbcr of the bcr gene (Figure 1 ) result in the formation of a bcr-abl gene expressing either the b2a2 or b3a2 mRNA variant (see Figure  3 ). The b3a2 is more prevalent than the b2a2. Both mRNA molecules are translated into a protein of 210 kDa. However, the b3a2 variant is 25 amino acids larger than the b2a2 variant. Whether the presence or absence of bcr exon b3 has implications for the clinical heterogeneity of CML has been the topic of many investigations. Inokuchi et al 50 suggested that the b3a2 variant might be related to thrombocytosis. However, this could not be confirmed by others. [51] [52] [53] Similar conflicting results have been reported for the correlation with interferon responsiveness. 54, 55 Since a large number of in frame bcr-abl fusions are possible, the number of variant bcr-abl genes leading to functional fusion proteins are in theory vast. 56 With regard to the abl gene variant translocations have been described lacking exon a2 of the abl gene leading to b3a3 and ela3 fusions 57 indicating a breakpoint in the abl gene between exon 2 and 3. However, alternative splicing or splicing defects could offer an alternative explanation for the detected transcripts. 58, 59 Deletion of the abl exon 2 encoding for 58 amino acids partly forming the SH3 domain, might have implications for the leukemogenic potential of these alternative proteins, since SH3 deletion mutants of ABL have an increased tyrosine kinase activity. 47 For the bcr gene a much greater heterogeneity in breakpoints is present. A breakpoint in the mbcr gives rise to the ela2 fusion in the majority of Ph-positive ALL patients 60 ( Figure 3 ). Sometimes this variant can also be detected in Phpositive CML patients. The resulting p190 has an elevated tyrosine kinase activity as compared to the p210 61 and is associated with a more aggressive leukemia. Pane et al 20 analyzed three patients with a clinical CML variant known as neutrophilic-chronic myeloid leukemia where the predominating cell is the neutrophil. All three cases analyzed showed a breakpoint in the bcr gene downstream from the Mbcr and mbcr. This new breakpoint region was called the bcr, giving rise to a new fusion variant joining bcr exon e19 (c3) with abl exon 2 leading to a protein of 230 kDa. The same fusion of bcr exon c3 to abl exon 2 has also been suggested to correlate with thrombocytosis and moderately elevated leukocyte numbers. 62, 63 On the basis of these findings the hypothesis was formulated that with an increasing moiety of bcr in the bcrabl fusion the resulting protein causes a more benign CML variant. 20, 64 Another variant translocation has been reported where bcr exon e6 is fused to abl exon 2, 56 giving rise to a protein slightly larger than 185 kDa.
The abl-bcr gene:
The research concerning the 9;22 recombination has traditionally been focussed on the bcr-abl gene and its products. However, as a consequence of the reciprocal recombination an abl-bcr gene is also formed. Coexpression of the abl-bcr gene might play a role in biological and/or clinical heterogeneity in CML. Melo et al demonstrated that abl-bcr mRNA can be detected in 60% of CML patients 65, 66 and in eight out of nine ALL patients. 67 Yin et al 68 made an effort to correlate abl-bcr mRNA presence with interferon-alfa responsiveness. They showed that 7/10 cases (70%) of the abl-bcr positive patients had a major cytogenetic response on interferon-alfa treatment whereas only (3/13) 13% of the abl-bcr negative patients showed a major cytogenetic response. 68 However, Melo et al 69 found no such correlation when analyzing 105 interferon-alfa-treated CML patients. The putative biological and/or clinical relevance of the abl-bcr gene expression remains enigmatic especially since until now no ABL-BCR protein has been detected in patient samples.
Transforming potential of the bcr-abl gene
To unravel the role of the bcr-abl gene product in leukemogenesis, different groups have performed transfection studies. Heisterkamp et al 70 showed that a metallothionein promotordriven bcr-abl construct coding for the p190 can induce acute myeloid and lymphoid leukemia in transgenic mice. Furthermore, when using a construct coding for p210 the emergence BCR-ABL fusion proteins. The exons of the BCR protein are indicated with dark gray boxes and are numbered 1 to 23. The exons of the ABL protein are light gray boxes and numbered 1 to 11. Breakpoints in the m-bcr region of the bcr gene give rise to the fusion of bcr exon 1 (e1) with abl exon 2, generating a fusion protein of 185 kDa. Breakpoint in the M-bcr region give rise to the fusion of either bcr exon 13 (b2) with abl exon 2 or to the fusion of bcr exon 14 (b3) with abl exon 2. Both fusions generate a protein of about 210 kDa. Breakpoints in the u-bcr give rise to the fusion of bcr exon 19 (c3) with abl exon 2 generating a fusion protein of about 230 kDa.
of T cell leukemia in transgenic mice could be demonstrated. 71 Transfection of bone marrow cells with constructs coding for p210 or v-abl and subsequent reinfusion in sublethally irradiated syngeneic recipient mice showed the emergence of transplantable CML-like leukemias. [72] [73] [74] In agreement with these results, retroviral expression of bcr-abl in bone marrow cells enriched for hematopoietic stem cells led to deregulated growth and growth factor independence. 75 All these results underline the central role of bcr-abl in the leukemogenesis of CML.
However, several lines of evidence suggest that other aspects apart from the presence of the bcr-abl gene are important for the full understanding of leukemogenesis. Firstly, Fialkow et al 4, 76 showed, using B cell cloning techniques, that in five out of 14 female CML patients with a glucose-6-phosphate dehydrogenase heterozygosity, a significant excess of Ph negative B lymphoid cell lines with the same G6PD-enzyme polymorphism could be demonstrated. These results suggested that prior to the acquisition of the Philadelphia chromosome clonal development could be present. Secondly, Biernaux et al 77 demonstrated that bcr-abl mRNA can be detected in the blood of 22 out of 73 normal adults, in the blood of only one out of 22 healthy children but not at all in umbilical cord blood, suggesting that the chance for acquiring the Ph increases with age and that the presence of the bcrabl gene does not have to result in leukemia per se. The presence of bcr-abl transcripts in the blood of healthy individuals has been confirmed by the group of Melo. 78 Thirdly, transcripts were found in almost half of the patients with essential thrombocythemia; during a follow-up period of 20 months they did not develop signs of CML. 79 Lastly, transgenic mice expressing the transfected gene in all tissues, exclusively develop hematologic malignancies, suggesting that the p190/p210 can induce malignancy only in permissive cells. 70 In conclusion, bcr-abl plays a central role in leukemogenesis although for a full understanding of CML other aspects such as those mentioned above should be further explored.
Signal transduction
Although the transforming potential of the BCR-ABL protein is well established, exactly how this protein exerts its transforming effect is still unclear. This section will try to give insight into BCR-ABL signal transduction.
General aspects of signal transduction
In the last decade vast progress has been made in unraveling cellular signal transduction. Several distinct routes have been discovered showing a great diversity in signalling which is largely augmented by intense cross-talk between different routes. In short, three routes relevant for the understanding of BCR-ABL signal transduction will be outlined, however, it should be mentioned that much more is known about signal transduction but for clarity not all is depicted (Figure 4) .
The mitogen activated protein kinase (MAPK) pathway is initiated after the binding of a ligand by a membrane-bound tyrosine kinase, such as the epidermal growth factor receptor, leading to dimerization of the receptor. Subsequently, the SH1 activity of both molecules results in cross-phosphorylation on tyrosine residues. Adapter proteins such as GRB2, SOS interact via the phosphorylated tyrosine residues with their SH2 domains leading to activation of the membrane-bound RAS protein, which in turn can activate the RAF protein leading to signal cascade activating the MAP kinases resulting in altered gene expression.
The stress activated protein kinase (SAPK) also called the Cjun amino-terminal kinase (JNK) is another important protein which can be activated by various cytokines and after stress conditions such as heat shock by, for example, SPKR (SH3 domain containing proline-rich kinase) leading to activation of the AP1 transcription complex.
Alternatively, the phosphorylated tyrosine residues of the receptor can bind and activate the phospholipase C (PLC) gamma enzyme. The subsequent hydrolysis of the phosphatidyl inositol 4,5-biphosphate (PIP2) generates two second messengers: inositol 1,4,5-triphosphate (IP3) and diacylglycerol (DAG). IP3 mobilizes intracellular calcium which can bind to protein kinase C (PKC) altering its hydrophobicity leading to relocalization to the plasma membrane. Subsequently, DAG can bind to and activate the PKC enzyme leading to phosphorylation of proteins on serine and threonine and activation of other protiens such as phospholipase D (PLD), a novel player in signal transduction.
A much more rapid signalling is moderated through the Jaks and the TYKs. These tyrosine kinases are activated after the binding of cytokine or interferons to their receptors. 80 The activated Jaks and TYKs phosphorylate cytoplasmic transcription factors known as the STATs which upon activation migrate to the nucleus and alter gene expression.
Binding of the adapter protein Shc to cytokine receptor can lead to activation of the PI3-K (phosphatidyl-inositol 3 kinase) and AKT route. The 62 kD dok protein is a protein which can link cytokine receptors to the RAS pathway.
Signal transduction in CML
Signal transduction studies in CML have to a large extent been performed in artificial systems such as IL-3-dependent cell lines, which have been immortalized with bcr-abl constructs; this cellular background should be kept in mind while interpreting the studies described.
A central question in BCR-ABL signal transduction is how the ABL SH1 domain is activated in the chimeric protein. The observation that the dimerization domain of the BCR part of the chimeric protein moderates homo-oligomerization of the BCR-ABL has shed new light on this problem. The dimerization of these tyrosine kinase molecules leads to cross-phosphorylation on tyrosine residues of the BCR-ABL protein. 44 The cross-phosphorylated tyrosine residues subsequently form docking sites for several adapter molecules and enzymes, thereby activating signal transduction pathways. Other lines of investigations confirmed this key role for dimerization. Firstly, the fusion of the ABL protein to the estrogen receptor led to activation of the oncogenic potential of the fusion protein after estrogen-induced dimerization as demonstrated in NIH 3T3 fibroblasts. Secondly, in Rat-1 fibroblasts and Ba/F3 cells, the fusion of the transcription factor TEL with ABL resulted in the helix-loop-helix-mediated oligomerization of the fusion protein and activation of the SH1 activity. 81 Thirdly, fusion of the c-ABL with the extra-in trans-membrane part of the erythropoietin receptor led to a dose-dependent activation of the c-ABL kinase activity by erythropoietin. 82 Another important aspect of BCR-ABL signal transduction is the cytoplasmic localization of the fusion protein. Van Etten et al 83 demonstrated that in NIH 3T3 fibroblasts and COS-1 cells, the deletion of a small N-terminal part of the ABL gene leads to a redistribution of the ABL protein to the cytoplasm and activation of the transforming potential. 83 In addition, the BCR part of the protein probably can direct the fusion protein to the cytoplasm. The actin binding domain of ABL subsequently determines the precise localisation of the BCR-ABL protein in the cytoplasm. 27 Deletion of the C-terminal actin binding domain of c-ABL, in c-abl/erythropoietin receptor fusion protein model, results in three times delayed death of mice from leukemia after exposure to erythropoietin. 84 The activitated BCR-ABL protein is then able to phosphorylate and activate different cytoplasmic substrates. The ABL kinase activity can phosphorylate other molecules such as the CK2 serine/threonine kinase thereby mediating BCR-ABL signal transduction effects. 85 Of great interest is the observation that 1651 transformation of cell lines with BCR-ABL leads to abnormalities of cytoskeletal function such as a dramatic increase in the motility of the cells as observed using time-lapse video. This effect could be counteracted using interferon-alfa. 86 The CRKL protein is constitutively phosphorylated on tyrosine in CML cells. 25, 87 CRKL is an adaptor protein, with two SH2 and one SH3 domain, which can interact with the BCR-ABL protein, and signals down to mSOS1 88 and paxillin, a 68-kDa focal adhesion protein which is constitutively phosphorylated in CML. 89 CRKL can also interact with CBL (Casitas B-lineage lymphoma) protein in CML cells. 90 The CBL protein can induce B cell and myeloid leukemias in mice. CBL/CRKL complexes can also be induced by different cytokines such as interleukin-3 and erythropoietin. 91 Interestingly, mutation of the proline-rich region of the BCR-ABL protein, the docking place of the SH3 region of CRKL, does not lead to impairment of BCR-ABL to render myeloid cells growth factor independent, 92 suggesting that BCR-ABL transforming potential does not purely rely on signalling via CRKL.
STAT 5 93 and to a lesser extent STAT 1 and 3 94 are phosphorylated in Ba/F3 and FDC-P1 cells expressing the bcr-abl gene. Expression of the bcr-abl mutant Y177F (substitution of the tyrosine residue on position 177 by a phenylalanine) in Ba/F3 cells prevents the interaction with the GRB2 adaptor protein and leads to a decrease in the phosphorylation of the STAT 1 and 5 proteins. 95 Incubation of normal progenitors with the c-kit ligand resulted in tyrosine phosphorylation of molecules, such as the 62 kDa dok protein. The fact that the 62 kDa dok protein is constitutively phosphorylated in CML blast cells makes this protein of great interest for studying transformation by BCR-ABL. 96, 97 Growing interest is concerned with the stress activated protein kinase (SAPK) or Cjun amino-terminal kinase (JNK) influencing gene expression which can be activated by BCR-ABL via a RAS-dependent pathway involving germinal center kinase related (GCKR) 98 or via a RAS-independent pathway involving SH3 domaincontaining proline-rich kinase (SPRK). 99 Still more interactions of the BCR-ABL are being investigated such as with the BCR protein itself, the PLC-gamma enzyme, the Shc protein 100 linking BCR-ABL to the P13-K in AKT pathway, 99 the Ph-P53 protein, the c-Fes protein, 101 the Syp protein, 102 and the Bap-1 protein, a member of the 14-3-3 type signal transduction molecules, 103 which has been implicated in the Raf signal transduction.
In conclusion, the transforming potential of BCR-ABL is dependent on the dimerization, the cytoplasmatic localization and subsequent phosphorylation and activation of different signal transduction routes (see Figure 5 ).
The role of RAS:
The elucidation of the MAPK pathway has been one of the major breakthroughs in signal transduction research in the last decade. Deregulation of members of this cascade such as RAS have been investigated and are of great importance in, for example, acute myeloid leukemia. Although RAS mutations are very rare in chronic phase CML cells, the MAPK pathway is probably very important for the transforming activity of BCR-ABL as indicated by the following studies: (1) Pendergast et al 104 demonstrated that BCR-ABL exists in a complex with GRB2 in insect cells and this interaction is mediated by the GRB2 SH2 domain with the phosphorylated tyrosine, Y177, in the BCR-ABL protein; (2) mutation of the tyrosine Y177 abrogates the GRB2 interaction with BCR-ABL and results in loss of RAS activation and transforming potential in Rat-1 fibroblasts; (3) Puil et al 105 could
demonstrate in vitro the same Y177-mediated link between BCR-ABL and GRB2 and mSOS1, thereby signalling down to the RAS pathway; (4) Sawyers et al 106 demonstrated that overexpression of a dominant-negative mutation of RAS in Rat-1 fibroblasts can abolish the transforming potential of BCR-ABL; (5) Odai et al 107 identified a novel protein named pp135, by using GST fusion proteins containing the full-length GRB2 protein. This protein of 133 kDa has phosphatase activity and contains one SH2, one SH3 and one proline-rich sequence. In CML-derived cell lines the pp135 was constitutively phosphorylated and associated with Shc and BCR-ABL. Of interest is the observation that MAPK is not always a downstream target of the BCR-ABL protein as demonstrated in BA/F3 cells. Research on the role of RAS in CML is ongoing, identifying downstream targets for RAS signalling such as BCL2, 108 increasing the depth of the knowledge of BCR-ABL signal transduction. [109] [110] [111] One should, however, keep in mind that not all signalling by RAS goes through the MAP kinase pathway; as mentioned before, RAS can also signal down to, for example, the SAPK pathway.
The role of MYC:
The MYC protein belongs to the so called immediate-early genes, it is localized in the nucleus and functions as a transcription factor. 112 Myc dimerizes with its partner Max and the complex alters transcription after DNA binding. 113 Myc activation in the presence of growth factors leads to growth. 114 However, expression of Myc in the absence of growth factors can lead to the induction of apoptosis. 115 Mutations in the myc gene and gene amplification or deregulated expression are common features in malignancies. Sawyers et al 116 demonstrated that overexpression of a dominant-negative Myc mutant abrogates the transforming potential of BCR-ABL in Rat-1 fibroblasts. In a later study, using complementation analysis, the same group showed that BCR-ABL mutants with non-functional SH2 domains could be rescued by overexpression of Myc in fibroblasts. 117 However, in the same system, mutants with impaired GRB2 binding of BCR-ABL could not be rescued by Myc overexpression, indicating that part of the transforming ability of bcr-abl depends on Myc and another part depends on GRB2 signalling. This suggests that Myc and Ras may operate in different pathways for the BCR-ABL protein.
Signal transduction in Ph-negative CML
Up to 10% of patients with a CML-like disease lack the Philadelphia chromosome. 118 However, Morris et al 119 demonstrated that in two out of five Ph-negative patients the same bcr-abl gene rearrangements could be observed as in the Phpositive samples. These Ph-negative but bcr-abl-positive cells are often the result of variant translocations and can be detected using fluorescence in situ hybridization (FISH), genomic Southern blotting and RT-PCR techniques. 120 Ph-negative bcr-abl-positive rearrangements have not only been detected in CML but also in ALL. Results from a study of 13 Ph-negative but bcr-abl-positive samples indicated that complex translocations leading to the generation of the bcr-abl fusion were the result of two consecutive translocations indicating that at least four chromosome breaks were necessary. 121 In some cases the bcr-abl fusion could even be detected on chromosome 9 instead of on the Ph. 122 In order to determine possible differences in their clinical behavior Ph+/bcr+ and Ph−/bcr+, leukemias were compared. The Ph−/bcr+ cases showed the same clinical behavior as the Ph+/bcr+ patients. 118 Moreover, both groups showed a very comparable response to interferon-alfa. These results indicate that Ph− but bcr+ leukemias behave very similarly to classic CML.
Gene rearrangements involving the ETV6 gene have been recently found in many different leukemias; 123 ETV6 is a member of the ets family of transcription factors.
124 ETV6/ABL fusion has recently been observed in BCR-ABL-negative CML. 125 The fusion protein can confer growth factor independence in Rat-1 fibroblasts. 82 Okuda et al 126 investigated the ETV6/ABL fusion protein, and compared it with the BCR-ABL proteins p210 and p190. They demonstrated that the ETV6/ABL protein is present in the cytoplasm and is associated with the cytoskeleton generating a similar substrate specificity as the BCR-ABL proteins leading to phosphorylation of ras-GAP, Shc, CRKL, CBL, paxillin and the Stat proteins. 126 In juvenile CML no bcr-abl translocation is present but in 30% of cases N-ras mutations have been demonstrated. 127 It can be hypothesized that deregulation of RAS signal transduction might be the central theme in chronic myeloid leukemias. 128 
Altered cellular functions in CML
The disruption of normal signal transduction has consequences for cellular functions thereby possibly generating the leukemic phenotype. This section will address the altered growth, apoptosis and adhesion characteristics in CML.
Growth characteristics:
The growth characteristics of CML progenitors are probably very similar to those of their normal counterparts, which might be one of the reasons why this disease is so difficult to treat effectively. 129 Chronic phase CML cells are not growth factor independent and demonstrate normal response to growth factors. 75 Moreover, proliferation is probably not the result of an abnormal autocrine or paracrine mechanism. 130 However, on a closer look many altered proliferation characteristics can be identified. Eaves et al 131 showed that CML progenitors cultured in vitro are actively cycling regardless of the presence or absence of a stromal layer, whereas normal cells are out of cycle on a stromal layer. Accumulation of CML cells would thus be explained by the continuous cycling and production of primitive Ph-positive progenitors. A recent study by the same group suggested that CML cells are characterized by a decreased probability of self-renewal combined with an increased probability of differentiation. 132 CML cells probably die off at a quicker rate during in vitro culture as compared to their normal counterparts. This interesting difference in behavior between in vivo and in vitro growth has led to purging experiments of CML patient derived cells by in vitro culturing (see section 'Purging by bone marrow culturing' for more details). Clarkson et al 133 formulated an alternative theory known as the 'discordant maturation' theory. In this model it is not the most primitive cell that gives rise to the expansion but the partially differentiated pool of CML cells that undergo additional cell divisions at a later stage of development.
Proliferation of CML progenitors might be explained by the observation that after growth factor withdrawal BCR-ABL pre-vents downregulation of cyclin-dependent kinase activity and cell cycle arrest. 134, 135 Another explanation might be the unresponsiveness of CML progenitors to the growth inhibiting effect of macrophage inflammatory protein 1␣ (MIP-1␣). 136 MIP-1␣ selectively inhibits growth of primitive progenitors. 137 Interestingly, MIP-1␣ receptors are present on CML-derived CD34-positive cells and unresponsiveness might thus be caused by signalling defects at a level downstream of the receptor. 138 Using a temperature sensitive V-ABL tyrosine kinase it could be demonstrated that impaired inhibition of growth by MIP-1␣ was mediated by the ABL kinase. 139 Conflicting results, albeit generated in a different test system indicate that another chemokine, namely MCP-1 and not MIP-1␣, blocked the cycling of primitive normal progenitors whereas CML progenitors were not inhibited. 140 An alternative mechanism for CML expansion has been formulated after the observation that bcr-abl-negative progenitors have a growth advantage over the malignant clone in the absence of stem cell factor (SCF). 141 In this context it is interesting to note that BCR-ABL and the SCF receptor might interact with one another. In addition, it has been demonstrated that SCF alone can induce selective expansion of CMLderived CD34
+ cells. 142 Expansion of CML progenitors would thus be caused by an altered response to stem cell factor as compared to normal progenitors. In this respect it is interesting to note that transforming growth factor beta (TGF beta) has been demonstrated to counteract the SCF-induced proliferation of CML progenitors. 143 Taken together these results indicate that CML cells do have specific altered growth characteristics as compared to control cells probably depending on the presence of several growth inhibitory and stimulatory molecules, which add to the expansion of the malignant clone in vivo.
Apoptosis:
The accumulation of mature myeloid cells is one of the most striking features in CML. The discovery of programmed cell death or apoptosis has prompted intense research on this phenomenon. 144 Several lines of evidence indicate a role for BCR-ABL as suppressor of apoptosis: (1) Bedi et al 145 showed that bcr-abl expression inappropriately prolongs the growth factor withdrawal-induced survival of CML myeloid progenitors by inhibiting apoptosis which could be reversed by antisense oligonucleotides. They concluded that the inhibition of apoptosis by BCR-ABL is the major cause for the expansion of the leukemic clone in CML. Moreover, they showed that BCR-ABL protein confers resistance to apoptosis and a prolonged cell cycle arrest at G2/M phase after induction of DNA damage. (2) McGahon et al 146 showed that resistance to the induction of apoptosis by chemotherapeutics was conferred by bcr-abl expression. In addition, the induction of a temperature sensitive v-abl could suppress drug-induced apoptosis in an IL3-dependent mouse mast cell line. 147 (3) Retroviral transduced murine myeloid cells turned resistant to induction of apoptosis by protein tyrosine kinase inhibitors. 148 The same cells were protected from DMSOinduced apoptosis by activated abl oncogenes. 149 Further delineation of the apoptotic events show that exposure to etoposide results in DNA fragmentation and cleavage and activation of procaspase-3 whereas in BCR-ABLpositive cell lines these events are delayed. 150, 151 Transformation of HL60 cells with BCR-ABL led to a decreased expression of the BCL2 protein and an upregulation of BCLxl. Targeting of BCL-xl with antisense oligodeoxynucleotides led to a decreased BCL-xl level and an increased sensitivity to staurosporine-induced apoptosis in BCR-ABL transformed cells. 152 Another study evaluated the effect of levels of BCR-ABL and showed that only high level expression was able to confer apoptosis resistance. 153 Interestingly, induction of apoptosis with C2-ceramide was accelerated in BCR-ABL transformed cells whereas TNF-alfa-mediated apoptosis induction was blocked by BCR-ABL. 154 Others, however, could not reproduce the reduced susceptibility to apoptosis. Gordon's group 155 performed experiments suggesting that there might be maturation stage-specific differences in susceptibility to apoptosis.
Adhesions defects:
Adhesion of hematopoietic cells to the bone marrow microenvironment is of prime importance for regulated hematopoiesis. Different families of adhesion molecules mediating cell-cell and cell-extra-cellular matrix interactions can be identified: (1) the intergrins with, for example, the very late antigen (VLA) molecules and the leukocyte function antigen (LFA-1) molecule all composed of an alfa and a beta subunit; (2) the selectins with, for example, E-selectin (ELAM) P-selectin and L-selectin; (3) the CD44 cluster; and (4) the immunoglobulin supergene family with, for example, LFA-3, the intercellular adhesion molecules (ICAM), the vascular adhesion molecule (VCAM) and the neural cellular adhesion molecule (N-CAM (CD56)). Specific interaction between adhesion molecules and their receptors, for example, between VCAM-1 on bone marrow fibroblasts and VLA-4 hematopoietic progenitor cells plays an important role in the process of homing and egress of hematopoietic progenitors.
The premature egress of partially differentiated myeloid cells out of the bone marrow to the peripheral blood has prompted research for possible adhesion defects in CML. Petzer et al 156 demonstrated that not only CML progenitors are present at elevated numbers in the peripheral blood but that also Ph-negative long-term culture initiating cell (LTCIC) are present in increased numbers as compared to normal controls, indicating that the mechanisms causing the premature egress of Ph-positive progenitors might also influence the normal counterparts. Other groups also found elevated numbers of normal progenitors in the blood of CML patients in early chronic phase.
It can be hypothesized that the premature egress of immature cells from the bone marrow not only reflects an adhesion defect but could also reflect the inability of immature myeloid cells to home the bone marrow microenvironment; CML cells would thus be trapped inside the blood compartment. This phenomenon could play a role in the potential benefit of autologous bone marrow transplantation: although reinfused bcrabl-positive cells can participate in relapse 158 a decreased ability to home might result in a preferential outgrowth of the benign reinfused cells. Gordon et al 159 showed that CML cells have a defective adhesive capacity to cultured stromal layers as compared to normal cells. In addition, CML cells show decreased adhesion to fibronectin. 160 Interferon-alpha has been demonstrated to induce, among other changes as outlined in section 'Interferon-alpha', changes in the biochemical composition of cultured stromal layers and can increase the adhesive potential of CML cells. 161 These results suggest that the clinical effect of interferon-alpha treatment might be accomplished by changing the microenvironment in the bone marrow, enhancing adhesion of CML progenitors and thus reinstalling the normal regulatory properties of stromal cells.
Several adhesion molecules have been implicated in the decreased adhesive behavior of CML cells: (1) 165, 166 could demonstrate an altered ␤-1 integrin receptor function of CML progenitors, which could be restored after treatment with interferon-alpha or exposure to BCR-ABL antisense oligodeoxynucleotides, and resulted in adhesion of hematopoietic progenitors to bone marrow stromal cells and microenvironmental inhibition of CML progenitor proliferation. Two other studies emphasize the possible role of ␤-1 integrin. Firstly, MIP-1␣ production, induced after treatment of stromal cell layers with interferon-alpha, can result in upregulation of ␤-1 integrin-dependent adhesion to stromal cells 167 and secondly, monoclonal antibody-induced activation of ␤-1 integrin function results in increased adhesion to fibronectin. 168 The impaired ␤-1 integrin function might also affect the function of the proteoglycan adhesion receptor CD44. 169 Transfection studies showed that BCR-ABL protein can induce constitutive phosphorylation of focal adhesion proteins such as paxillin, vinculin, p125-FAK, talin and tensin. 170 Another study emphasized the interaction of p210 with CBL involving focal adhesion proteins such as paxillin. 171 Coimmunoprecipitation studies indicated the physical linkage between p210 and paxillin mediated by CRKL. 89 These interactions with focal adhesion proteins might contribute to the adhesion defects in CML.
Taken together, these results show that many functional and phenotypical adhesion defects can be observed in CML cells. Interferon-alpha can restore several of these defects which might be important for its clinical efficacy.
Genetic aspects of CML
Chronic myeloid leukemia is probably one of the best examples of the multistep theory of cancer whereby multiple mutations lead to a full blown malignant phenotype. 172 This section deals with the question of how the Ph is formed and which oncogenes are involved in clonal evolution.
Formation of the Philadelphia chromosome
Recombination by chance and subsequent clonal selection at the basis of growth advantage might be a simple but appealing mechanism to explain the occurrence of the Ph although more complicated alternative mechanisms have also been suggested, three of which will be discussed below.
(1) Haas et al 173 showed by cytogenetic G-banding of centromeric polymorphisms that in all 15 cases analyzed the bcr moiety of the bcr-abl gene was of maternal origin and the abl moiety of the bcr-abl gene was of paternal origin. They suggested that the bcr and abl genes are imprinted. Genomic imprinting is a phenomenon whereby genes are expressed depending on the parental origin. This non-Mendelian epigenetic inheritance is probably caused by DNA methylation. 174 This methylation or coupling of CH3 groups to, for example, promoter sequences can lead to a transcriptional inactive gene. Imprinting has been demonstrated in a growing number of genes such as the igf-2 and wt-1 genes. 175 The paper by Haas et al suggested that an active maternal bcr gene derived from chromosome 22, was coupled to an active paternal abl gene derived from chromosome 9. Coupling of a paternal bcr to a maternal abl gene would lead to a transcriptionally inactive bcr-abl gene, which therefore cannot initiate malignant transformation. This hypothesis implicates that only one abl allele and one bcr allele can be transcriptionally active. However, Fioretos et al 176 showed via RT-PCR detected polymorphisms on the bcr gene that both alleles are expressed. These results were confirmed by others. 177 Furthermore, Litz et al 178 demonstrated that in three cases all bcr moieties of the bcrabl gene were from paternal origin as detected with polymorphism analysis. Melo et al 179 showed that both abl alleles are expressed and contribute equally to the bcr-abl gene. Since Haas et al 180 used cytogenetic techniques directed to the centromere region, a high incidence of somatic recombination could lead to a combination of these at first sight conflicting results. 181 (2) Aberrant methylation of the bcr gene has been described by different groups. 182, 183 Litz et al 184 analyzed 50 chronic phase CML patients and showed that 20 had aberrant hypermethylation of the Mbcr region involved in the translocation. Moreover, three out of eight samples obtained from CML patients in remission after interferon therapy or autologous bone marrow transplantation, showed aberrant methylation of the bcr in these Ph-negative cells suggesting that these methylation aberrations may precede the translocation event.
(3) Identifications of the specific regions involved in the formation of the Ph showed that the breakpoints are often localized in ALU repeats [185] [186] [187] or in the close proximity of ALU repeats. 188 ALU repeats are DNA sequences of about 140 base pairs arrayed in tandem repeats. The high density of ALU repeats in the large intron sequences involved in the recombination could make the involved chromosomes prone to acquire the translocation. 9 Other sequence elements such as Chi-like octamers, immunoglobulin heptamers and alpha protein binding sites have also been suggested to play a role in the chromosomal rearrangement leading to the Ph. 9 
Blast crisis CML
Progression to a blast crisis, manifested, for example, by less response to chemotherapy, increased leukocytosis with more immature forms, eosinophilia and/or basophilia, correlated with the appearance of additional cytogenetic abnormalities such as 22q−, loss of the Y− chromosome, isochromosome 17, trisomy 8, trisomy 9, an additional Ph or inversion of chromosome 16. 189, 190 Specific clonal evolutions have different prognostic implications depending on, for example, the predominance of the clone in the metaphase analysis. 191 Although in chronic phase CML both T 192 and B 193,194 lineage involvement is demonstrated, the stem cell nature of the malignant clone becomes even more apparent in the diverse nature of blast crisis cells exhibiting features of all lineages. Patients have been described with an eosinophilic blast crisis, 195 a basophilic blast crisis, 196 erythroid blast crisis, 197 megakaryocytic blast crisis 198 and lymphoid blast crisis. 199 Moreover, samples can exhibit multilineage involvement such as T lymphoid/myeloid bilineage crisis 200, 201 or myeloid/ lymphoid/megakaryocytic trilineage crisis. 197, 202 Blast crisis with an undifferentiated phenotype 203 and a Burkitt lymphoma-like blast crisis have also been described. 204 However, the majority of blast crisis CML are either myeloid or lymphoid. Myeloid blast crisis is three to four times more frequent than lymphoid blast crisis. [205] [206] [207] Response to therapy is very poor showing a median survival of 3 months for a myeloid blast crisis and 6 months for a lymphoid blast crisis. [208] [209] [210] In addition, patients with lymphoid blast crisis are younger, have a lower WBC count, an increased probability of extramedullary crisis, a shorter duration of chronic phase and a more favorable response to therapy. 208 Although genomic instability might be present even before the appearance of the Ph, thus giving rise to the formation of the Ph, once the bcr-abl gene is present there seems to be an inclination to acquire additional mutations. Smoking is known for its ability to increase genetic instability and analysis of 173 CML patients showed that smoking correlated highly significantly with both incidence of blast crisis and overall survival. 211 Clonal evolution was observed in a patient both in the advent of and during the blast crisis since specific subclones could be detected before overt lymphoid crisis that was not identical to the clone present during blast crisis. 212 Another study showed that three subsequent blastic transformations in one patient all showed different rearrangements indicating that multiple clones were generated from the CML progenitor cell, suggesting that there is not one exclusive way to clonal evolution in CML. 213 Impressive is the clonal evolution in the K562 cell line showing extensive amplification of the bcr-abl gene. Up to 24-fold gene amplification could be demonstrated. 214 
Oncogenes in blast crisis CML
During the clonal evolution of CML cells towards the blast crisis the genome becomes increasingly unstable. Probably the activation of oncogenes and the inactivation of tumor suppressor genes are important. Transformation of cells with an inducible BCR-ABL construct show the generation of subclones with unchanged BCR-ABL constructs but with growth independence and constitutive phosphorylation of STAT5 protein indicating additional activating mutations. 215 In this section genetic aspects of the clonal evolution towards blast crisis CML are reviewed.
Microsatellite instability and loss of heterozygosity:
A well known marker for genomic instability or 'mutator phenotype' is the microsatellite instability (MSI). Microsatellites are DNA sequences containing a variable number of tandem repeats (VNTR). Mutation proneness will lead to polymorphisms in these sequences. Although microsatellite mutations are not oncogenic as such they occur concomitantly with mutations in mismatch repair genes. 216 Moreover, microsatellite instabilities are prevalent in many inherited forms of cancer such as hereditary non-polyposis colon cancer (HNPCC). Another marker for genomic instability is loss of heterozygosity (LOH) whereby one allele is deleted. Deletion of one allele and mutation of the other is a common phenomenon in cancer. Inactivation of tumor suppressor genes requires inactivation of both alleles. A frequently observed LOH at the same genomic spot often indicates the location of a tumor suppressor gene. Wada et al 217 analyzed 19 CML samples in transition and 20 CML samples in chronic phase. The results suggested that MSI and/or LOH might be related to CML evolution. Mutations in the microsatellites have been demonstrated in a CML sample and disappeared after interferon-alpha therapy. 218 Mori et al 219 analyzed 30 CML patients in the transition from chronic phase to accelerated phase or blast crisis. They analyzed 82 microsatellite markers and found LOH on at least one focus in 21 of 30 cases (70%). However, Silly et al 220 analyzed 48 CML patients in blast crisis and compared the DNA with chronic phase samples and with material extracted from buccal epithelial cells. In total, 517 paired samples were analyzed for LOH and MSI. They demonstrated a low incidence of LOH and the absence of MSI in 12 loci of different genes including the Rb gene and the Wilms tumor gene. In contrast to Wada et al they concluded that MSI and LOH, of the genes analyzed, are unlikely to be involved in the progression of CML to blast crisis. A low incidence of MSI in CML and other hematologic malignancies was demonstrated by others as well. 216, 221 Loss of imprinting (LOI) is another mechanism and has been demonstrated for the insulin-like growth factor gene (IGF2) in the progression from chronic phase to accelerated phase CML leading to bi-allelic expression of the gene. 222 Although the role of MSI, LOH and LOI is thus under dispute, various oncogenes and tumor suppressor genes have been implicated for their involvement in the transition towards blast crisis CML and will be reviewed in the next two sections.
Activation of oncogenes in blast crisis CML:
The activation of several oncogenes has been investigated in blast crisis CML.
Firstly, overexpression of the Evi-1 gene (ectopic virus integration site-1) which is located on chromosome 3 and encodes a nuclear DNA binding protein, is a consistent observation in leukemias with t(3;21) translocations. 223 Evi-1 has transforming potential as demonstrated with transfection studies in RAT-1 fibroblasts. Evi-1 overexpression is detected with a high frequency in CML blast crisis samples [224] [225] [226] and is associated with dysmegakaryopoiesis. 227 Sequence analysis of the breakpoints of two blast crisis CML-derived cell lines showed truncation of the Evi-1 indicating that expression of a truncated Evi-1 might play a role in the progression towards blast crisis of CML. 228 Secondly, although signalling via RAS is probably a central point in CML leukemogenesis (see section 'The role of RAS') mutations of RAS molecules are very rare in chronic phase CML. Analysis of 29 chronic phase CML samples and 22 blast crisis samples for mutations in the N-RAS, H-RAS or K-RAS genes showed no occurrence in chronic phase samples whereas only two blast crisis samples had K-RAS mutations. 229 Another study suggested that extramedullary blast crisis in the form of a myeloblastoma is associated with RAS mutations. 230 However, no N-RAS mutations in a total of 121 blast crisis samples could be detected in other studies. 231 Thirdly, myc gene amplification, using a semi-quantitative PCR, has been demonstrated in CML progression. 232 Sequential analysis of samples obtained from a CML patient showed 8-to 16-fold amplification of the c-myc gene during transformation whereas this could not be detected in chronic phase samples. 233 Fourthly, an interesting new development concerns the telomerase activity of malignant cells. Telomeres form the end of eukaryotic chromosomes and the gradual loss of telomeric DNA progresses with ageing. 234, 235 Loss of telomeres results in cell senescence. Most tumor cells contain telomerase activity whereas most normal tissues lack such activity. 236 Analysis of samples derived from CML patients showed increased telomerase activity as compared to normal cells which further increased during blastic transformation. [237] [238] [239] In conclusion, the evi-1, myc and telomerase genes are 
Inactivation of tumor suppressor genes:
An alternative for the oncogenic activation, with regard to the acquisition of a malignant phenotype, is the inactivation of tumor suppressor genes. Several tumor suppressor genes have been investigated in blast crisis CML.
Firstly, for the important tumor suppressor gene p16 240 homozygous deletions have been found in five out of 10 lymphoid blast crisis samples whereas these could not be demonstrated in non-lymphoid blast crisis. 241 Secondly, the retinoblastoma (Rb) tumor suppressor gene has a function in cell cycle regulation and is implicated in numerous cancers. 242 Analysis of 22 CML blast crisis samples showed that in all five megakaryoblastic samples no Rb protein could be detected whereas none of the other 17 samples showed any such abnormality. 243 On the other hand, analysis of 27 CML blast crisis samples with PCR single-strand conformation polymorphism (SSCP) showed no molecular lesions of the Rb gene in all cases, even in the one megakaryoblastic sample analyzed. 244 Thirdly, the best known tumor suppressor gene is p53 and inactivation is an almost universal step in carcinogenesis. 245 The p53 gene has a function as the 'guardian of the genome': in the case of DNA damage p53 protein induces a G 1 arrest enabling repair of DNA damage. However, if the damage is too extensive p53 protein induces apoptosis. In the absence of p53 protein no G 1 arrest is induced and the cell with DNA damage can proceed with cell divisions. 246 The p53 gene is located on the short arm of chromosome 17 and the p53 protein binds to the DNA as a homo-dimer. Inactivation of p53 can be achieved by deletions and/or via inactivating point mutations. Wild-type p53, dimerized with mutant p53, is non-functional.
Ahuja et al 247 demonstrated that alterations in the p53 genes are rare in chronic phase CML but are frequent in blast crisis samples. In addition, analysis of sequential samples of the same patient showed that a point mutation in the coding region of the p53 gene was absent in chronic phase, present in first blast crisis and disappeared again after induction of remission. 248 Furthermore, cytogenetic aberrations of the short arm of chromosome 17 correlated well with loss of p53 function. 249 Loss of p53 gene function is implicated in 25% of the CML progressions towards blast crisis. 250 Evaluation of 13 CML patients in chronic phase and in blast crisis CML showed LOH for the p53 gene in eight cases. 251 However, analysis of 21 CML blast crisis samples for mutations in the so-called 'hot spots' regions, where p53 mutations are concentrated, showed that these were rare. 252 Taken together, inactivating mutations of the p16 and p53 tumor suppressor genes probably play an important role in some blast crisis CML patients. The variable involvement of several tumor suppressor genes and oncogenes in the clonal evolution of CML point out that progression towards blast crisis is probably a very heterogeneous process.
Treatment of CML
The treatment of CML patients has been changing steadily over the past decades. This section deals with the treatment of CML patients with chemotherapy, interferon-alpha and allogeneic bone marrow transplantation.
Chemotherapy
Reduction of the leukocyte numbers can be readily accomplished in chronic phase CML using hydroxy-urea or busulfan. In a multicenter study, 441 CML patients were randomized either to receive hydroxy-urea or busulfan. The median survival for the hydroxy-urea-treated patients was 58.2 months vs 45.4 months for the busulfan-treated patients; a statistically significant difference. 253 However, treatment with these agents does not prevent blast crisis. Intensive treatment with high-dose chemotherapy is remarkably ineffective in CML. 254, 255 Although occasional sustained remissions have been described, in general, chemotherapeutic intervention does not result in prolonged overall survival. 256, 257 In this respect this disease behaves differently from other hematological cancers such as acute myeloid leukemia and acute lymphoblastic leukemia where intensive chemotherapy can induce sustained remission. Blast crisis CML is even more chemotherapy insensitive. Recently, several agents have been tried in blast crisis CML: carboplatin evaluated in 36 patients showed only brief responses, 258 fludarabine (a nucleoside analog) was tested in nine patients and no lasting response was observed. The same held true for four patients treated with deoxycoformycin. 259 A pilot study investigated the effect of all-trans retinoic acid; no benefit of this treatment was observed in the patients with advanced disease. 260 The effect of decitabine was investigated in 37 CML patients and with this hypomethylating agent in some patients response could be observed. 261 Several cell biological features of CML can be significant in this respect. Firstly, the stem cell nature of the malignant progenitor might be relevant, since stem cells are probably out of cycle for most of the time, thereby decreasing the vulnerability for most chemotherapeutical agents.
Secondly, stem cells express the multiple drug resistance gene mdr-1. The mdr-1-derived Pgp protein effectively pumps out all kinds of natural product chemotherapeutics. In this respect it is of interest that mdr-1 expression has been demonstrated in chronic phase and in blast crisis material although non-Pgp-mediated drug resistance might be even more important. 262 Thirdly, BCR-ABL protein can mediate apoptosis resistance. The result could be that even when chemotherapeutic treatment results in extensive DNA damage of the cell, it will not proceed towards apoptosis (see section 'Apoptosis').
Although cure by means of chemotherapy is probably very difficult to achieve in CML, it can be argued that efficient reduction of the clonal population will result in a reduced probability of further clonal evolution, thus postponing the transition towards a lethal blast crisis and prolonging life expectancy.
Interferon-alpha
Interferon-alpha treatment is an effective cytoreductive therapy in chronic phase CML: up to 73% of patients achieve a hematologic remission and up to 18% achieve a complete cytogenetic remission. 263 Moreover, in about one in every five patients treated with interferon a complete disappearance of the Ph-positive clone could be demonstrated as shown by cytogenetic analysis and Southern blotting. 264 A meta analysis of seven randomized trials concluded that IFN is favorable for survival. 265 Efforts are directed to further improve the results of interferon treatment by using combinations with other agents such as GM-CSF 266 and low-dose ARA-C. Chronic phase CML patients were randomized to receive either IFNalpha or IFN-alpha in combination with monthly courses of cytarabine. After 3 years 85.7% of 360 patients from the IFN alpha-cytarabine group survived whereas 79.1% of 361 patients from the IFN group survived, a significant difference. 267 For more extensive information on interferon therapy we would like to refer to a review by Goldman. 268 Taken together, interferon-alfa is an important new drug for the treatment of CML patients. More research is warranted to increase the depth of understanding how interferon exerts its effects. This might help to understand why it is not effective in all patients.
Allogeneic bone marrow transplantation
Allogeneic bone marrow transplantation with a HLA-identical sibling is the therapy of choice for CML patients. A 38% leukemia-free survival at 10 years was observed for patients transplanted in first chronic phase. 269 These figures are worse for patients transplanted in accelerated phase or in blastic phase due to an increased relapse incidence as well as transplantrelated mortality. The results of allogeneic bone marrow transplantations are improving due to improved transplantation protocols and supportive care.
Only a minority of CML patients are eligible either because they are too old or no HLA-identical sibling is present. The maximum age for an allogeneic transplantation is shifting towards higher age, thus increasing the applicability of this treatment modality. 270 Another possibility to increase the number of patients eligible for BMT is the use of partial mismatched or matched unrelated donors (MUD). With regard to increased toxicity, MUD transplantations should be used only for young patients. 271 We would like to refer to a review by Sawyers 272 for more extensive coverage on this subject.
Immunologic aspects of CML
The BCR-ABL fusion protein could be a target for the immune system thus offering possibilities for immune therapy in CML. Immunologic aspects of CML become evident during BMT where immune-mediated graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) can be discerned. This section will focus on these phenomena and describe the efforts to delineate the immune mechanisms involved.
Graft-versus-host disease
Despite all efforts to improve on transplant outcome allogeneic transplantation remains associated with a high mortality. 273 Goldman et al 274 showed that at 4 years after bone marrow transplantation 196 of the 405 patients included in the study had died, mostly as a result of GVHD. Although prevention of GVHD by T cell depletion does result in lower GVHD-related mortality, higher relapse rates by limiting the GVL effect can result in a lower leukemia-free survival. 275 In this respect it is interesting to note that BMT with twins is possible 276 but does result in higher relapse rates most probably due to the absence of the GVL effect. 277 The recognition of the GVL reaction has led to the infusion of donor leukocytes as a salvage therapy in relapsed CML patients after BMT. This was first performed by Kolb et al 278 who demonstrated high remission rates. However, GVHD and bone marrow suppression are major complications leading to 18% mortality at 1 year. Efforts to try to improve on this include the infusion of donor leukocytes before overt hematologic relapse, 279 infusion of lower dosages of donor cells 280 or infusion of leukocyte subsets. 281 Several clinical and experimental studies suggest that GVHD is transmitted by CD8 + T cells whereas GVL is transmitted by CD4 + T cells. Adoptive immunotransfer using CD4
+ cells shows induction of complete remissions. 282 
BCR-ABL as a target for the immune system
Immune response can be divided into two groups: major histocompatibility complex (MHC) unrestricted immune response, mediated by natural killer cells (NK) or lymphocyte activated killer cells (LAK) and the MHC restricted immune response, mediated by CD4 + and CD8 + T cells. The importance of immunological targeting becomes apparent when considering the observation that bcr-abl expression is able to confer apoptosis resistance for chemotherapy but not against NK cells and cytotoxic T lymphocytes (CTLs). 283 NK cells in CML are probably not derived from the malignant clone but show features of reduced functionality. 284 On activation with IL-2 or other cytokines NK cells acquire cytotoxic potential. In vitro studies in CML indicate that IL-2 activated NK cells can eliminate CML progenitors whereas normal hematopoietic progenitors are spared. 285 This effect of IL-2 has also been established in culture systems with leukemic cell lines. 286, 287 Antitumor activity of IL-2 has been explored both in vitro and in vivo in combination with donor cell infusion at relapse after BMT. 288, 289 Specific CTLs against BCR-ABL epitopes can be detected in CML patients, suggesting that anti-CML-directed immune response is of importance in CML. 290 Vaccination of mice with synthetic junction peptides can result in the generation of peptide specific CD4 + cells 291 showing that breakpoint peptides can be presented by class II molecules. Peptides derived from the b3a2 protein investigated for the ability to elicit class I-restricted CTLs show that this was possible in half of the donors tested and in all the HLA-A3 donors tested and cytolytic response could be observed. 292 This MHC-restricted binding of BCR-ABL junction peptides warrants identification of new tumor-associated epitopes with less severe restriction making such target epitopes of more general usage for CML patients. 293 A new approach makes use of the antigen presenting ability of dendritic cells. Dendritic cells can be generated by the culturing of mononuclear cells in the presence of GM-CSF, TNFalpha and IL-4. Culturing of CML cells can thus generate dendritic cells derived from the malignant clone. 294 Potent CTLs have been generated after co-cultivation of these dendritic cells with autologous T cells. 295 A Japanese study used peptide pulsing to load dendritic cells with BCR-ABL-derived peptides followed by stimulation of allogeneic T cells. 296 The generated T cells showed cytotoxic activity against CML cells. A similar approach was followed by Mannering et al, 297 who showed specific response of HLA-DR1-restricted b3a2-specific CD4 + T cells to dendritic cells pulsed with b3a2 peptides. These cells could offer an elegant tool for eliciting an anti-leukemia effect, thereby controlling, for example, residual disease.
Minimal residual disease
The detection of residual cells derived from the malignant clone, left after treatment, has been the focus of many studies, addressing the question of whether cure and relapse can be predicted from the numbers of these minimal residual disease (MRD) cells.
Cytogenetics and PCR
The classical approach for the measurement of MRD is the analysis of metaphases with cytogenetic techniques. Cytogenetic analysis is performed on actively dividing cells. However, as a result of treatment, for example with interferon, dividing cells are often scarce 298 and typically only 25 metaphases are evaluated. Moreover, the actively dividing cells might not represent the relevant population with regard to leukemia-free long-term marrow repopulating ability.
The polymerase chain reaction (PCR) is nowadays widely used since it is a very sensitive technique. Various aspects are currently under investigation. Firstly, the expression of the bcrabl gene has been suggested to increase during disease progression. 299 Thus, increasing numbers of bcr-abl transcripts might reflect not only increasing cell numbers but also clonal evolution. Secondly, elegant PCR strategies have been developed making the identification of the molecular breakpoint possible in some CML patients. 300 Comparison between DNA-based PCR and RT-PCR, however, gave the same results. 301 Thirdly, several studies have compared the results of PCR on blood vs bone marrow-derived samples and since no differences were found, MRD measurement does not require bone marrow sampling. 302 Treatment with interferon-alpha can result in hematologic remission in up to 70% of patients and a complete cytogenetic remission can be detected in up to 20% of patients. RT-PCR analysis of samples obtained from CML patients, treated with interferon-alpha, in complete remission, demonstrated that bcr-abl mRNA can be detected in the majority of samples. 303 Interferon-alpha is probably able to reduce bcr-abl mRNA levels below the detectable levels in only about 3% of CML patients. 304 Luckily, positivity in the PCR is not correlated with a fast relapse. 305 Long-term follow-up of 18 CML patients with a cytogenetic response on interferon-alpha showed that 10 of 18 were negative at 42 months since cytogenetic remission as determined with a single step RT-PCR. 306 Also, after an allogeneic bone marrow transplantation most patients in clinical remission are positive in PCR and, similar to the situation with interferon-alpha, this does not have to lead to immediate relapse. 307 However, post-transplant PCR positivity is more frequent in patients transplanted in advanced phase CML. 308 In addition, patients receiving a T cell-depleted graft or patients without signs of GVHD are more likely to have a positive post-transplant PCR. 309 Sequential analysis of patient samples post-transplant showed that repeated PCR positivity and PCR positivity at more than 6 months post-transplant correlates with relapse. 310 Nevertheless, RT-PCR positivity at more than 10 years after transplant without signs of relapse has been reported. 311 Taken together these results clearly show the limitation of cytogenetics and standard PCR techniques with regard to predicting cure or relapse and prompted research for more refined techniques.
Quantitative PCR
In an effort to improve the clinical relevance of the RT-PCR techniques several methods have been developed to quantitate the bcr-abl message. The additional value of quantification would be to guide therapeutic intervention with the aim to improve outcome for CML patients in hematologic remission but in molecular relapse, for example, by applying donor leukocyte infusion.
For the quantitative measurement of the bcr-abl mRNA most commonly a competitor is added to the PCR. The competitor is amplified in the same reaction vessel and amplified with the same oligonucleotide primers. The relative intensities of the target and competitor reveal the number of target molecules in the sample. The most ideal competitive RT-PCR makes use of a RNA competitor since then the efficiency of the cDNA synthesis is incorporated into the assay as well. Moreover, the ideal competitor generates a PCR fragment of similar length since the efficiency of the PCR is very much dependent on the length of the PCR product. As an example of such an approach, Thompson et al 312 used a RNA competitor generating a PCR product of the same length as the target, an additional Xho1 restriction site was incorporated to discriminate the target from the competitor. Others used a DNA competitor with an 8 base pair deletion 313 or a DNA construct with an insertion. 314 The numbers of bcr-abl mRNA molecules in samples of patients in complete remission after IFN therapy have been demonstrated to be highly variable 315 but an increase predicted relapse. 316 Analysis of 98 CML patients treated with an allogeneic bone marrow transplantation showed that of the 69 patients with repeatedly low levels of bcr-abl mRNA only one relapsed whereas of the 29 patients with increasing levels 21 relapsed. 317 Analysis of 163 CML patients with quantitative PCR showed a good correlation with cytogenetics and was able to demonstrate BCR-ABL transcripts in all patients with complete cytogenetic response. 318 The use of quantitative PCR eliminates the use of repeated bone marrow sampling.
In conclusion, quantitative PCR can be an important tool for the measurement of MRD.
Alternative approaches to determine MRD
Several alternative approaches have been developed for MRD detection. Firstly, with the nucleic acid-based amplification of cDNA (NASBA) technique, using three different enzymes in one reaction at one temperature, specific RNA sequences can be amplified with a similar sensitivity as with PCR. 319 Secondly, MRD can be assessed for the presence of the bcr-abl protein with Western blotting techniques. 320 The presence of the bcr-abl gene rearrangement can also be detected with genomic Southern blotting techniques. 302 Both generate good results although sensitivity is lower as compared with RT-PCR.
A major disadvantage of all these molecular techniques is that no information is generated with regard to the functionality of the cells generating these fusion molecules. As discussed in the previous section, long living lymphocytes could generate positive results with these techniques but have no further clinical relevance. On the other hand, if these signals had been generated by hematopoietic stem cells then relapse could be imminent. A way to address these problems is by phenotyping the cell population relevant for MRD. Hematopoietic progenitors are known to reside inside the CD34-posi-1659 tive compartment. 321 Separation of these cells by means of FACS is routine nowadays. These cells can than be analyzed with different molecular techniques such as fluorescence in situ hybridization (FISH). FISH for the detection of bcr-abl gene has been first described by Arnoldus et al 322 and Tkachuk et al. 323 Probes for both the abl and the bcr genes are hybridized on to the DNA of the cells and are detected with different fluorochromes. Fusion signals indicative for the presence of the bcr-abl gene can be observed using a fluorescence microscope. Modifications of the original procedures include the use of breakpoint spanning YAC clones, 324 the use of inter-ALU PCR-generated probes, 325 the detection with FISH probes on hyper-metaphases, 326 the use of a third probe with a different fluorochrome to enhance sensitivity 327 and the use of probes generating fusion signals on both altered chromosomes. 328, 329 FISH can be applied both on dividing and on non-dividing cells and has been performed on FAC-sorted cells. 330 Factors that influence the interpretation of interphase FISH (I-FISH) are the size of the nuclei and the genomic position of the abl breakpoint. 331 Using I-FISH it has been suggested that relative closeness of bcr and abl genes in the nucleus makes cells prone to develop the Philadelphia chromosome. 332 The most direct way to study the relevance of such MRD cells is by evalulating the growth potential with in vivo or in vitro assays. With regard to the in vitro assays, cells can be plated in, for example, the colony-forming unit granulocytemacrophage (CFU-GM) assay. During culturing in semi-solid medium individual cells generate colonies under the influence of specific hematopoietic growth factors. The generated colonies can than be analyzed with cytogenetics. 333 We conducted an experiment in which we compared a sensitive nested RT-PCR with interphase-FISH on CFU-GM colonies. 334 Individual colonies were split in two and analyzed with both techniques. We could demonstrate that BCR-ABL mRNA is present in all colonies harboring the bcr-abl gene and that I-FISH is a suitable technique for analyzing individual colonies. Molecular analysis of individual myeloid colonies, derived from CML patients in complete cytogenetic remission after interferonalpha a treatment demonstrated that these cells were derived from the malignant clone. 335 More primitive progenitors can be evaluated in the LTCIC assay in which the cells prior to plating in the CFU-GM assay are cultured for 5 weeks on top of a stromal feeder layer. 336 Again, the generated colonies can be analyzed for their molecular content. With regard to the in vivo assays, severe combined immune deficiency (SCID) mice are a frequently used model system for all kinds of cancers. Implantation of a fetal femur in SCID mice (Hu-SCID) provides a human bone marrow micro-environment thus establishing a model for stem cell engraftment. In such studies CML-derived cell lines and blast crisis samples showed rapid growth but chronic phase CML cells showed limited growth, although engraftment of chronic phase CML could be established. 337 In another study, highly purified stem cells isolated from CML patients after intensive treatment were injected into Hu-SCID mice. 338 Engraftment occurred and MRD could be evaluated. A new mouse model system is the non-obese diabetic NOD/SCID mouse demonstrating good engraftment of mixed normal and BCR-ABL-positive cells, 339, 340 and reflecting CML biology. 341 Taken together, the use of all these different techniques such as PCR, quantitative PCR, Western blotting, Southern blotting, FISH, phenotypical characterization and functional analysis, make evaluation of tumor contamination possible and should be helpful in improving therapeutical protocols.
Investigational options
Although the numbers of CML patients eligible for allogeneic transplantation are increasing, at least 65% of patients will have to rely on alternative therapies. 342 As discussed earlier, treatment with interferon-alpha prolongs survival in the small group of patients with a complete cytogenetic response while the addition of ARA-C might result in further improvement. Nevertheless, for the majority of CML patients the inevitable progression towards the terminal blastic phase is awaiting. Therefore, investigational options such as autografting and purging are being currently explored.
Autologous bone marrow transplantation in CML
The rationale for autografting resides in the knowledge that nonclonal 343 Ph-negative hematopoietic progenitors reside inside the bone marrow of CML patients. 344 Moreover, incidentally observed complete and sustained remissions after busulfan treatment (see section 'Chemotherapy') show that these residual cells can restore normal bone marrow function. 345 The use of autografts dates back to the time before allogeneic transplanting and was first performed in blast crisis CML and later in accelerated phase CML 346 and chronic phase CML. 347 In some cases a complete cytogenetic conversion could be demonstrated post-transplant. 348, 349 Twenty-one CML patients treated in first chronic phase with an autotransplant showed a significantly longer survival at 5 years posttransplant as compared to conventional chemotherapy. 350 Compilation of the results from eight transplant groups encompassing 200 patients, indicate a plateau in the survival curve for patients treated with an autograft. 351 On the other hand, analysis of 22 chronic phase CML patients resistant to interferon-alpha and treated with an unpurged autograft showed no prolongation of survival. 352 However, all these results are single-arm studies with selected patient groups making firm conclusions hard to draw. 353 A major disadvantage of autografting as compared to allogeneic grafting is the lack of GVL. In this respect it can be argued that results obtained with autografts will at best resemble the results obtained with identical twins which have a probability of relapse of almost 60% at 1 year post-transplant. 354 Future protocols for autografting should thus employ techniques to induce anti-tumor activity of the immune system, for example, with the use of dendritic cells, presenting the fusion peptide to immune effector cells 294 (see section 'BCR-ABL as a target for the immune system').
Another drawback of autografting is the reinfusion of malignant cells which can result in the re-emergence of CML. It has been demonstrated that the percentage of reinfused malignant cells correlates with the number of Ph-positive metaphases post-transplant. 355 Moreover, marking studies as pioneered by Brenner et al 356, 357 have demonstrated that relapse after autologous bone marrow transplantation is at least partly caused by the reinfused malignant cells. 158 For acute myeloid leukemia purged grafts can result in a significantly lower relapse rate as compared to unpurged grafts. 358 These results indicate that it could be of importance to eliminate malignant progenitors from the autograft. Aspects of in vivo and in vitro purging will be dealt with in the next two sections.
In vivo purging
In vivo purging aims at reduction and hopefully elimination of the leukemic clone after which normal stem cells can be harvested and used for autografting. An example of such an approach is the protocol developed by Simonsson et al. They included 160 CML patients, not eligible for allogeneic bone marrow transplantation, to receive 6 months of hydroxy-urea with high-dose IFN followed by one to three courses of intensive chemotherapy. Forty-seven percent of the patients showed a significant reduction of the Ph-positive clone whereas 28% became Ph negative. 359 Of the patients who where Ph-negative bone marrow was harvested. Thirty patients underwent autologous bone marrow transplantation of which 10 were still Ph negative up to 64 month posttransplant.
An alternative method aims at the mobilization of Ph-negative bone marrow stem cells into the blood after chemotherapy in combination with cytokines. These peripheral blood stem cells have the advantage of being harvested via leukapheresis bypassing the need for general anesthesia. In addition, peripheral blood stem cell transplantation results in a faster hematologic recovery as compared to bone marrow transplant. 360 Several groups have analyzed different mobilization protocols for stem cell content: (1) Sutherland et al 361 analyzed leukapheresis products of 21 patients and demonstrated that LTCICs were present in these harvests. However, mobilized LTCICs demonstrated a more mature phenotype and were not able to generate a read-out at week 8 LTCIC. (4) Weaver et al 364 showed that increasing numbers of LTCIC can be mobilized into the blood with increasing dosage of stem cell factor in combination with standard chemotherapy and G-CSF. (5) The use of G-CSF in combination with GM-CSF demonstrated that different cytokines mobilize different subsets of progenitors. 365 Taken together, these results indicate that primitive as well as more mature hematopoietic progenitors can be mobilized depending on the mobilization protocol used.
The mobilization of Ph-negative stem cells in CML has been pioneered by Carella et al. 366 They used an intensive chemotherapy consisting of idarubicin, ARA-C and etoposide known as the 'ICE' regimen and G-CSF. The collection of Ph-negative, non-clonal 336 primitive hematopoietic cells was proven feasible in 12 out of 16 patients treated within 1 year of diagnosis, whereas for patients treated after 1 year of diagnosis only in 12 out of 33 was a Ph-negative collection possible. 367 Ten patients mobilized at diagnosis have been transplanted and five are Ph negative at 4 to 12 months post-transplant. Several groups have undertaken efforts to reproduce these results and improve on mobilization protocols. Firstly, Kantarjian et al 368 analyzed 55 CML patients treated with two different mobilization protocols and showed that 27% of the chronic phase CML patients had a Ph-negative harvest as determined with standard cytogenetic analysis. Secondly, Van den Berg et al 338 analyzed 14 CML patients after mobilization with the ICE regimen. Cytogenetic analysis showed that all accelerated phase or blast phase samples had 100% Ph-positive harvests whereas four out of five chronic phase CML patients had 100% Ph-negative harvests. However, FISH analysis of highly purified stem cells and transplantation of these cells in Hu-SCID mice showed that all transplant samples contained residual leukemia. Thirdly, Chalmers et al 369 treated 40 CML patients with a regimen containing idarubicin and ARA-C. Although 43% of the harvests were 100% Ph negative using standard cytogenetic analysis only 3% were negative with Southern blot analysis and all harvests were positive in the PCR for the bcr-abl message. Fourthly, in an effort to reduce toxicity and improve the stem cell yield, mobilization with G-CSF alone, 370 cyclophosphamide in combination with G-CSF 371 or hydroxy-urea in combination with G-CSF 372 have been investigated. Taken together, these results indicate that also with much milder therapy, as compared to the ICE regimen, Ph-negative stem cells can be mobilized, underlining the lack in basic knowledge of how stem cells are mobilized from the bone marrow.
We analyzed the harvest of mobilization procedures for tumor contamination and CFU-GM and LTCIC content. 373 Individual colonies derived from both assays were analyzed with I-FISH and were compared with standard cytogenetics. Molecular analysis of individual colonies correlated well with the cytogenetic analysis. We could also demonstrate an output per single LTCIC of on average 67 colonies/clusters which is much higher than previously reported.
Probably, combinations of specific chemotherapeutics with certain chemokines could lead to improved harvests with less contamination of Ph-positive cells. However, these results indicate that it might be difficult to find regimens that result completely in Ph-negative stem cell harvests. Therefore, it can be anticipated that in vitro purging will remain necessary to eliminate all malignant progenitors from the autograft.
In vitro purging
Anti-sense approach:
Since the protein product of the bcrabl gene (p210) is leukemogenic, 75 elimination of the BCR-ABL protein or mRNA is a logical approach to cure leukemia. Antisense oligodeoxynucleotides (ASODNs) have the potential to block specific gene expression. 374 The formation of RNA-DNA hybrids induces RNAse H-mediated degradation of RNA. Moreover, the RNA-DNA hybrid cannot be translated. Both effects result in protein synthesis inhibition. The potential of this strategy for CML has been demonstrated showing antisense-mediated inhibition of CML colony formation. 375, 376 Strictly speaking, an antisense effect can only be proven when a marked decrease in the amount of bcr-abl mRNA and P210 protein can be demonstrated. Only a few studies have addressed this point. 377 In theory, suppression of p210 should lead to a reversal of the phenotype. However, the temporary exposure to ASODNs will only lead to cure if the target cells are killed, otherwise tumor progression will proceed after withdrawal of the ASODNs. Several groups have demonstrated induction of apoptosis after exposure to ASODNs. 146, 377 In order to enhance cell killing and making use of the elimination of the chemotherapy resistance conferring p210, a combination of ASODN treatment with, for example, mafosfamide in vitro purging could be very promising. 378, 379 The first clinical trial enrolled eight CML patients who were treated with an autologous bone marrow transplantation. 380 Before transplantation the stem cell harvest was exposed to BCR-ABL targeted antisense deoxyoligonucleotides. Results indicate that the treatment has low toxicity but also low efficacy in the patient group thus far analyzed. However, the following problems still have to be resolved. Phosphodiester linked oligonucleotides are easily degraded by nucleases. Several groups have tried to modify these ASODNs in order to increase the nuclease resistance. 376 Phosphorothioate ASODNs have a sulphur for oxygen substitution in the phosphate backbone of the DNA leading to higher nuclease resistance but also to a higher toxicity as well as aspecific interactions. 374, 381 Methylphosphonate ASODNs are not charged thus generating less aspecific interactions. The poor solubility of these ASODNs, however, makes delivery via liposomes or phosphodiester tailing necessary. 376, 382 An alternative way to enhance delivery of ASODNs in the cell is by reversibly permeabilizing the cell with streptolysine-O 383, 384 or by using cationic lipids. 385 Much debate has arisen about the specificity of the ASODNs. 386 With cells containing b2a2 transcripts, efficacy of ASODNs could be readily demonstrated. 375, 379, 380 in contrast to b3a2 containing cells. 377, 387 These observations led to the concept of sequence-specific but non-antisense 388 or sequence-dependent but not sequence-specific. 389 Sequence dependent but non-antisense effects can probably be caused by the interaction of specific nucleotide sequences such as TAT and GCC with proteins. 390 Vaerman et al 391 demonstrated a novel non-antisense mechanism of ASODNs. They showed that the antiproliferative effect of ASODNs is correlated with the absence of a cytosine residue at the 3Ј position. Exonucleases break down the ASODNs and only when a low proportion of d-CMP is present can the ASODN exert its antiproliferative effect.
Retroviral antisense constructs have the advantage that the antisense treatment is continuous and the effect is not dependent on the possible temporary transcriptionally silence of the bcr-abl gene in CML stem cells. 392 Although suppression of the p210 was demonstrated, co-suppression of the normal bcr-gene might be a problem. 393 This might be circumvented by using constructs coding for ribozymes. These are engineered RNA enzymes directed against the bcr-abl mRNA junction and aim to splice the fusion mRNA thus leading to elimination of the p210. Several groups have designed their own ribozymes and have shown the potential of this approach. [394] [395] [396] [397] [398] Alternatively, targeting of genes essential for leukemic survival such as c-myb 399 or combining ASODNs against bcr-abl with ASODNs against c-myc are currently being explored. 400 In vitro experiments have demonstrated the potential of these procedures. Pilot protocols using harvests purged in vitro with c-myb ASODNs showed no interference with engraftment but results on clinical outcome have to be awaited. 401 
Purging by bone marrow culturing:
The uncontrolled proliferation of CML progenitors regardless of the presence of a stromal layer 131 results in the rapid decline of CML cells during culture. 402 These observations triggered further studies on purging effects of bone marrow culturing. Bone marrow sample cultures derived from four CML patients at diagnosis showed the emergence of Ph-negative progenitor cells. 344 A problem for clinical application might be the loss of long-term repopulating cells. 403 However, prolonged maintenance of these cells was possible using murine stromal feeder layers. 404 Moreover, autografting of bone marrow cultured for 10 days was shown to deliver multilineage reconstitution. 405 In total 22 patients have been autografted after 10 days in vitro culture by the Vancouver group. 406 Shortly after engraftment most patients showed a very substantial number of Ph-negative cells in the bone marrow. However, almost all patients became Ph positive during follow-up. A comparable study using cultured autografts for nine CML patients showed that two died due to graft failure and one due to transplant-related toxicity. Six of the patients remain in chronic phase CML with two in complete cytogenetic remission 3-4 years post-transplant. 407 Whether these efforts will result in longer survival has to be awaited. Moreover, this approach is very laborious and prone to deliver infectious agents to immune compromised patients.
Other purging modalities:
Currently a myriad of purging modalities are being investigated.
(1) Selection of Ph-negative progenitors on the basis of phenotypical differences has been investigated by several groups. 408 Wognum et al 409 demonstrated that the erythropoietin receptor can be detected on CML cells whereas it is absent on normal CD34-positive cells. Visani et al 410 showed that IL-2 receptors are inducible on CML cells whereas they are not on normal cells. Verfaillie et al 411 demonstrated that bcr-abl-negative progenitors can be isolated from CML samples on the basis of the expression of HLA-DR. HLA-DRnegative CD34-positive cells are more likely to be derived from non-leukemic clones as compared to HLA-DR-positive CD34-positive cells. Analysis of 27 early chronic phase CML samples showed that 80% of HLA-DR-negative/CD34
+ isolates were negative in the PCR for the bcr-abl mRNA and no Ph could be detected. Moreover, large-scale purification of HLA-DR-negative CD34-positive cells could be performed which could open the way to clinical application. 412 Similar efforts to select benign progenitors on the basis of CD38 413 or Thy-1 expression 414 have been performed. (2) A very rational approach is the downmodulation of the tyrosine kinase activity of the p210 protein with tyrosine kinase (PTK) inhibitors. Herbimycin inhibits the growth of bcrabl-positive cells in vitro whereas Ph-negative cell lines were very insensitive. 415 Synthesis of new PTK blockers known under the name tyrphostins showed that two of them have the potency to inhibit the tyrosine kinase activity of p210 which resulted in erythroid differentiation of K562 cells. 416 The PTK inhibitor CGP 57148 has been demonstrated to possess a high specificity for the abl PTK and was able to reduce bcr-ablpositive CFU-GM colony growth whereas normal colony growth was hardly affected. 417, 418 Another PTK inhibitor, genistein has been demonstrated to selectively reduce bcr-ablpositive colony growth. 419 PKC modulation can be an alternative for interference with the altered signal transduction in CML. 420 Our group has demonstrated that the PKC modulator bryostatin can inhibit leukemic outgrowth while stimulating normal hematopoiesis. 421 Bryostatin has been demonstrated to reduce CML colony growth and induce macrophage-like differentiation. 422 We have demonstrated that at the LTCIC level bryostatin can induce a six-fold higher reduction of colony growth as compared to the control samples. 423 (3) Mafosfamide is an agent with a high toxicity for hematopoietic progenitors although stem cells seem to be rather insensitive. 424 Mafosfamide treated autografts in CML resulted in 100% Ph negativity in six out of nine patients although remission was not sustained. 425 Efforts to improve the efficacy of this agent include the use of the bone marrow protecting agent amifostine to broaden the differential effect of mafosfamide, 426 combination with antisense oligonucleotides 427 or combination with the selectivity of stromal adherence. 428 (4) Various cytokines have been used for in vitro purging experiments. Interferon-gamma has antileukemic potential in CML 429 and treatment with interferon-gamma for 24 h followed by culturing can result in efficient elimination of Phpositive cells. 430 Moreover, interferon-gamma can be used in combination with interferon-alpha and shows synergistic effects. II-4 can inhibit CFU-GM capacity up to 65% in a dosedependent manner. 431 The differential effect of MIP-1 alpha and stem cell factor on normal and Ph-positive progenitors as discussed earlier indicates a potential role for these molecules in purging. 140, 143 (5) Hyperthermic treatment has been investigated in acute myeloid 432 and lymphoid 433 leukemia indicating that thermic treatment of transplant material does not interfere with engraftment. Increased sensitivity of AML cells as compared to control cells for hyperthermia could be demonstrated. 434 For CML three studies have been published. The first demonstrated a hypersensitivity, after thermic treatment, of CML bone marrow mononuclear cells as compared with cells derived from healthy volunteers. However, these differences were not significant. 435 The second study showed enhanced elimination of bcr-abl positive cells lines by thermic treatment. 436 These results underline the potential of hyperthermia as a purging modality in CML. The third study was performed by us and demonstrated a selective loss of BCR-ABL-positive progenitors after thermic treatment, especially at the LTCIC level as determined by molecular analysis of individual colonies. 437 (6) Differential sensitivity for cryopreservation and subsequent thawing has been suggested to result in a preferential loss of bcr-abl-positive progenitors leading to Ph-negative reconstitution after unpurged bone marrow transplantation in CML. 438 Preliminary in vitro data indicate a higher sensitivity of CML-derived CFU-GMs as compared to control cells 439 and a selective elimination of bcr-abl-positive LTCICs. 440 (7) Other purging modalities use photo-sensitizers followed by light treatment, 441 eilatin 442 and 5-fluorouracil. 443 A promising agent is homoharringtonine which can induce hematologic remission in 72% of patients in advanced chronic phase CML, while a major cytogenetic response was observed in 31%.
Summary
Major progress has been made in the treatment of CML. Cure can only be achieved after allogeneic stem cell transplantation. However, for the majority of patients transplantation is not a treatment option. Progress in the knowledge of basic mechanisms of the bcr-abl expressing malignant cell will hopefully lead to new targets and towards new treatment modalities that can be utilized in the near future.
